The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
Schrader, J., Henneberg, F., Mata, R.A., Tittmann, K., Schneider, T.R., Stark, H., Bourenkov, G., Chari, A.(2016) Science 353: 594-598
- PubMed: 27493187 
- DOI: https://doi.org/10.1126/science.aaf8993
- Primary Citation of Related Structures:  
5LE5, 5LEX, 5LEY, 5LEZ, 5LF0, 5LF1, 5LF3, 5LF4, 5LF6, 5LF7 - PubMed Abstract: 
The proteasome is a validated target for anticancer therapy, and proteasome inhibition is employed in the clinic for the treatment of tumors and hematological malignancies. Here, we describe crystal structures of the native human 20S proteasome and its complexes with inhibitors, which either are drugs approved for cancer treatment or are in clinical trials ...